TP53 and cancer: Given that increased activity of RNR and hence dNTPs promote tumorigenesis, cell proliferation and survival [2–6], our findings suggest mutation of TP53 may result in deregulation of mTORC1 and concomitant upregulation of RNR to render cancer cells to survive stressful conditions but at the cost of increased mutation rate.